vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Primoris Services Corp (PRIM). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.9B, roughly 1.5× Primoris Services Corp). Primoris Services Corp runs the higher net margin — 2.8% vs -3.7%, a 6.5% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 6.7%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $121.1M). Over the past eight quarters, Primoris Services Corp's revenue compounded faster (14.7% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Primoris Services Corporation is a publicly traded specialty construction and infrastructure company based in the United States, with a particular focus on pipelines for natural gas, wastewater and water. As of 2014 it was a Fortune 1000 company.
BHC vs PRIM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.9B |
| Net Profit | $-103.0M | $51.7M |
| Gross Margin | — | 9.4% |
| Operating Margin | 17.0% | 4.2% |
| Net Margin | -3.7% | 2.8% |
| Revenue YoY | 9.3% | 6.7% |
| Net Profit YoY | -205.1% | -4.2% |
| EPS (diluted) | $-0.30 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.9B | ||
| Q3 25 | $2.7B | $2.2B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.6B | $1.7B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.4B | $1.6B | ||
| Q1 24 | $2.2B | $1.4B |
| Q4 25 | $-103.0M | $51.7M | ||
| Q3 25 | $179.0M | $94.6M | ||
| Q2 25 | $148.0M | $84.3M | ||
| Q1 25 | $-58.0M | $44.2M | ||
| Q4 24 | $98.0M | $54.0M | ||
| Q3 24 | $-85.0M | $58.4M | ||
| Q2 24 | $10.0M | $49.5M | ||
| Q1 24 | $-64.0M | $18.9M |
| Q4 25 | — | 9.4% | ||
| Q3 25 | — | 10.8% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | 10.6% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 11.9% | ||
| Q1 24 | — | 9.4% |
| Q4 25 | 17.0% | 4.2% | ||
| Q3 25 | 23.1% | 6.3% | ||
| Q2 25 | 17.5% | 6.7% | ||
| Q1 25 | 12.2% | 4.3% | ||
| Q4 24 | 21.8% | 5.0% | ||
| Q3 24 | 12.7% | 6.0% | ||
| Q2 24 | 16.2% | 5.5% | ||
| Q1 24 | 13.1% | 3.1% |
| Q4 25 | -3.7% | 2.8% | ||
| Q3 25 | 6.7% | 4.3% | ||
| Q2 25 | 5.8% | 4.5% | ||
| Q1 25 | -2.6% | 2.7% | ||
| Q4 24 | 3.8% | 3.1% | ||
| Q3 24 | -3.4% | 3.5% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | -3.0% | 1.3% |
| Q4 25 | $-0.30 | $0.94 | ||
| Q3 25 | $0.48 | $1.73 | ||
| Q2 25 | $0.40 | $1.54 | ||
| Q1 25 | $-0.16 | $0.81 | ||
| Q4 24 | $0.24 | $0.98 | ||
| Q3 24 | $-0.23 | $1.07 | ||
| Q2 24 | $0.03 | $0.91 | ||
| Q1 24 | $-0.17 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $535.5M |
| Total DebtLower is stronger | $20.8B | $469.9M |
| Stockholders' EquityBook value | $-554.0M | $1.7B |
| Total Assets | $26.4B | $4.4B |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $535.5M | ||
| Q3 25 | $1.3B | $431.4M | ||
| Q2 25 | $1.7B | $390.3M | ||
| Q1 25 | $1.1B | $351.6M | ||
| Q4 24 | $1.2B | $455.8M | ||
| Q3 24 | $719.0M | $352.7M | ||
| Q2 24 | $595.0M | $207.4M | ||
| Q1 24 | $733.0M | $177.6M |
| Q4 25 | $20.8B | $469.9M | ||
| Q3 25 | $21.0B | $486.0M | ||
| Q2 25 | $21.7B | $603.1M | ||
| Q1 25 | $21.5B | $612.0M | ||
| Q4 24 | $21.6B | $734.8M | ||
| Q3 24 | $21.5B | $903.7M | ||
| Q2 24 | $21.7B | $933.0M | ||
| Q1 24 | $22.1B | $951.7M |
| Q4 25 | $-554.0M | $1.7B | ||
| Q3 25 | $-565.0M | $1.6B | ||
| Q2 25 | $-764.0M | $1.5B | ||
| Q1 25 | $-1.2B | $1.4B | ||
| Q4 24 | $-1.3B | $1.4B | ||
| Q3 24 | $-1.2B | $1.4B | ||
| Q2 24 | $-1.2B | $1.3B | ||
| Q1 24 | $-1.1B | $1.2B |
| Q4 25 | $26.4B | $4.4B | ||
| Q3 25 | $26.8B | $4.6B | ||
| Q2 25 | $27.3B | $4.5B | ||
| Q1 25 | $26.4B | $4.2B | ||
| Q4 24 | $26.5B | $4.2B | ||
| Q3 24 | $26.5B | $4.2B | ||
| Q2 24 | $26.5B | $4.0B | ||
| Q1 24 | $26.9B | $4.0B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.39× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $142.9M |
| Free Cash FlowOCF − Capex | $403.0M | $121.1M |
| FCF MarginFCF / Revenue | 14.4% | 6.5% |
| Capex IntensityCapex / Revenue | 3.3% | 1.2% |
| Cash ConversionOCF / Net Profit | — | 2.76× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $340.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $142.9M | ||
| Q3 25 | $405.0M | $182.9M | ||
| Q2 25 | $289.0M | $78.5M | ||
| Q1 25 | $211.0M | $66.2M | ||
| Q4 24 | $601.0M | $298.3M | ||
| Q3 24 | $405.0M | $222.5M | ||
| Q2 24 | $380.0M | $16.1M | ||
| Q1 24 | $211.0M | $-28.5M |
| Q4 25 | $403.0M | $121.1M | ||
| Q3 25 | $314.0M | $148.4M | ||
| Q2 25 | $190.0M | $45.3M | ||
| Q1 25 | $96.0M | $25.6M | ||
| Q4 24 | $495.0M | $270.0M | ||
| Q3 24 | $334.0M | $158.8M | ||
| Q2 24 | $302.0M | $-8.1M | ||
| Q1 24 | $129.0M | $-38.9M |
| Q4 25 | 14.4% | 6.5% | ||
| Q3 25 | 11.7% | 6.8% | ||
| Q2 25 | 7.5% | 2.4% | ||
| Q1 25 | 4.2% | 1.6% | ||
| Q4 24 | 19.3% | 15.5% | ||
| Q3 24 | 13.3% | 9.6% | ||
| Q2 24 | 12.6% | -0.5% | ||
| Q1 24 | 6.0% | -2.8% |
| Q4 25 | 3.3% | 1.2% | ||
| Q3 25 | 3.4% | 1.6% | ||
| Q2 25 | 3.9% | 1.8% | ||
| Q1 25 | 5.1% | 2.5% | ||
| Q4 24 | 4.1% | 1.6% | ||
| Q3 24 | 2.8% | 3.9% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.8% | 0.7% |
| Q4 25 | — | 2.76× | ||
| Q3 25 | 2.26× | 1.93× | ||
| Q2 25 | 1.95× | 0.93× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | 6.13× | 5.53× | ||
| Q3 24 | — | 3.81× | ||
| Q2 24 | 38.00× | 0.32× | ||
| Q1 24 | — | -1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
